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Abstract Amino acid residues thought to comprise the catalytic
triad of HHV-6 proteinase were changed by site-directed
mutagenesis in the precursor form of the proteinase. By
monitoring the ability of each mutant proteinase precursor to
undergo autoprocessing, Ser116, His46 and His135 were
identified as catalytically crucial. An attempt was made to
mimic the catalytic triad arrangement of archetypal serine
proteinases by replacement of the second histidine, His135, by an
Asp. Instead of increasing the autoprocessing ability of the
His135Asp mutant HHV-6 proteinase precursor, this mutation
had a detrimental effect since the precursor persisted predomi-
nantly in its unprocessed form.
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1. Introduction
Human herpesvirus-6 (HHV-6) is one of eight human her-
pesviruses discovered to date. It is the causal agent of exan-
thema subitum [1] and has been implicated in a number of
human diseases, especially those a¡ecting immunocompro-
mised individuals [2^4]. The genome of each herpesvirus en-
codes a proteinase which plays a crucial role in the viral life
cycle [5]. The virally encoded assembly protein forms a scaf-
fold onto which the viral capsid is built [6,7] and cleavage near
the C-terminus of this substrate by the proteinase releases the
processed assembly protein from the capsid allowing viral
DNA to enter and replication to proceed.
The HHV-6 proteinase is synthesised as a polyprotein pre-
cursor consisting of 528 amino acids [8]. The N-terminal re-
gion constitutes the mature proteinase, whereas the C-termi-
nal part encodes an extended form of the assembly protein
(Fig. 1). Autoprocessing of the precursor occurs at two loca-
tions (Fig. 1): at the release (R) site, thereby generating the
mature form of the proteinase (residues 1^230); and at the
maturation (M) site, located towards the C-terminus of the
assembly protein [9].
In the present study, we identify by site-directed mutagen-
esis the catalytic residues that enable this proteolytic activity
to ful¢l its important function in the viral life cycle.
2. Materials and methods
2.1. Mutagenesis by overlapping extension PCR
The full-length proteinase precursor gene cloned into the expression
vector pDS56,6His(2)Xa served as template DNA for the PCR muta-
genesis reactions [8,9]. Mutations were introduced by two initial and
one subsequent PCR reaction. Pairs of forward and reverse oligonu-
cleotide primers (Pharmacia Biotech., St. Albans, UK) encoding the
required mutation (and, where possible, a unique restriction site to aid
screening) were used with partner wild-type reverse or forward oligo-
nucleotides to amplify two separate DNA fragments. The puri¢ed
fragments were subsequently combined and used as template DNA
in a ¢nal PCR employing the two wild-type £anking primers. The
nucleotide sequences of primers used and restriction sites introduced
are shown in Table 1. Following the veri¢cation of its nucleotide
sequence, each mutated DNA fragment was sub-cloned into the orig-
inal wild-type construct.
2.2. Expression and immunodetection
Wild-type and mutant constructs were transformed into the E. coli
strain M15, pDM1.1. Cells harbouring the plasmids were grown at
28‡C until an A600 = 0.8 was reached. Induction was with 1 mM
L-D-isopropyl-thiogalactopyranoside and samples were removed at
various times post-induction for analysis by SDS-PAGE followed
by Western blotting using primary antibodies recognising either the
mature HHV-6 proteinase (residues 1^230) or the assembly protein
(residues 285^528) [8]. Alkaline phosphatase conjugated anti-rabbit
IgG antiserum was used as the second antibody to detect immuno-
reactive bands [9].
3. Results
Alignment of the sequence of HHV-6 proteinase [8] with
those of the counterpart proteinases from other herpesviruses
identi¢ed three conserved residues (Ser116, His46 and His135)
which therefore had the potential to operate as the catalytic
triad in the enzyme’s active site. Accordingly, these three res-
idues were replaced (individually) within the context of the
precursor form of HHV-6 proteinase and the ability of the
mutated precursor proteins to undergo autoprocessing in E.
coli was investigated. Samples were removed at di¡erent time
points and analysed by SDS-PAGE followed by Western blot-
ting using antisera speci¢c for the proteinase (Fig. 2, upper
panels) and assembly protein regions (Fig. 2, lower panels),
respectively. Processing of the wild-type precursor at both R
and M cleavage sites (Fig. 1) to release the assembly protein
and generate the mature form of HHV-6 proteinase was ac-
complished within about 30^60 min (Fig. 2, i). In contrast,
when Ser116 was mutated to an Ala and the resultant Ser116-
Ala mutant proteinase precursor gene was expressed, no proc-
essing whatsoever was detected with either antibody (Fig. 2,
ii). Instead, a single immunoreactive band of V65 kDa per-
sisted throughout the entire time course. Since this is consis-
tent in size with that of the full-length, unprocessed proteinase
precursor, it would seem that the simple replacement of the -
CH2OH side-chain of Ser116 by -CH3 in the mutant Ala
variant completely removed the intrinsic ability of the protein-
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ase precursor to undergo autoprocessing at both R and M
sites.
A second potential residue to contribute to the catalytic
triad of the HHV-6 proteinase was identi¢ed by the same
token to be His46. Expression of the His46Ala mutant pro-
teinase precursor gene in E. coli resulted in the detection of
several immunoreactive bands, the largest and most predom-
inant of which migrated at 65 kDa (Fig. 2, iii). A band,
migrating slightly faster than the V65-kDa intact precursor
was also revealed and, at V61 kDa, this corresponds in size
to the full-length precursor that had undergone cleavage at its
M site (Fig. 1). The two further bands that were detected had
apparent molecular weights (V56 kDa and 52 kDa, respec-
tively) which cannot be accounted for by cleavage at either or
both of the R and M cleavage sites. It has been suggested [9]
that these bands arise as a result of the non-speci¢c action of
E. coli proteinases on the HHV-6 proteinase precursor.
The third potential catalytic site residue, His135, was mu-
tated to an Asp and the expression pro¢le for this mutant
proteinase precursor is shown in Fig. 2, iv. The pattern of
immunoreactive bands detected is closely similar to that ob-
tained for the His46Ala mutant precursor. In both cases, it is
readily apparent that the majority of the protein produced
persisted as the V65-kDa proteinase precursor throughout
the length of the time course examined; this is in total con-
trast to the rapid autoprocessing observed for the wild-type
proteinase precursor (Fig. 2, i).
4. Discussion
These data suggest that the catalytic triad in HHV-6 pro-
teinase consists of Ser116, His46 and His135, with Ser116
likely to act as the active site nucleophile.
The three-dimensional structure of HHV-6 proteinase is not
yet known but structures have been solved recently by X-ray
crystallography for the proteinases from the closely related
human cytomegalovirus [10^13], herpes simplex viruses-types
1 and 2 [14] and varicella zoster virus [15]. The equivalent
residues to Ser116, His46 and His135 in human cytomegalo-
virus, for example, are Ser132, His63 and His157 and the
crystal structure indicates that these three residues do indeed
lie spatially adjacent, in close juxtaposition to one another
[10^13]. Indeed, superposition of the Ser/His/His catalytic tri-
ad of mature HCMV proteinase with the corresponding
Ser195/His57/Asp102 catalytic triad residues of chymotrypsin
reveals that, despite the distinct overall folds, the three resi-
dues can be overlaid to within an rms deviation of 0.8 Aî [11].
The somewhat unusual nature of the catalytic triad in the
serine proteinases of the herpesviruses is re£ected in the pro-
teolytic e⁄ciency of these enzymes. Measurement of kinetic
parameters for the hydrolysis of peptide substrates by puri¢ed
HHV-6 proteinase [9] revealed that this enzyme, in common
with the proteinases from other herpesviruses, exhibited sub-
stantially lower values for the turnover number (kcat) relative
to those measured for archetypal serine proteinases such as
chymotrypsin. Since the viral proteinases have the serine nu-
cleophile and His46 (equivalent to His57 in chymotrypsin) in
common with their archetypal counterparts, it was thus con-
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Fig. 1. Schematic representation of the HHV-56 proteinase precur-
sor. Autoprocessing at the R and M sites releases the mature pro-
teinase from the N-terminus and generates a (C-terminal) form of
the viral assembly protein. The locations of the putative active site
residues that were mutated are indicated.
Fig. 2. Autoprocessing of wild-type and mutant HHV-6 proteinase precursors. E. coli harbouring plasmids encoding (i) wild-type, (ii) S116A,
(iii) H46A and (iv) H135D mutant proteinase precursors were induced with isopropyl-L-D-thiogalactopyranoside. Aliquots were removed at the
indicated times and analysed by SDS-PAGE followed by Western blotting using antisera speci¢c for the mature proteinase (upper panels) and
assembly protein (lower panels), respectively. Markers of Mr, approximately 67 000, 43 000 and 29 000, migrated as indicated.
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sidered that the reduction in catalytic e⁄ciency might result
from the replacement of Asp102 in the catalytic triad of the
herpesvirus proteinase by a second histidine (His135). It was
on this basis that His135 was mutated to Asp in the HHV-6
proteinase precursor. However, the His135Asp mutation, far
from increasing the intrinsic catalytic activity of the mutant
HHV-6 proteinase precursor, appeared to have a detrimental
e¡ect since the precursor persisted predominantly in its V65-
kDa unprocessed form throughout the length of the time
course studied (Fig. 2). In this context, it might also be of
value to compare the kinetic parameters for substrate hydrol-
ysis by an Asp102His mutant of chymotrypsin or trypsin [16]
with those of a wild-type herpesvirus proteinase, such as that
from HHV-6. The orientation of the catalytic Ser,His,His res-
idues in the herpesvirus proteinases may require additional
features to contribute to the stabilisation that is achieved so
readily by the classical serine proteinases. However, in bio-
logical terms, a herpesvirus encoding a proteinase with ‘too
high’ an intrinsic activity might be considered to be unfavour-
able since proteolytic cleavage must not take place until the
temporal and spatial requirements for capsid assembly are
met. Under such circumstances, the viruses may well have
evolved to produce a proteinase that is capable of only a
limited level of catalytic activity.
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Table 1
Mutagenesis oligonucleotides
Mutation created Direction Mutagenesis oligonucleotide sequence (5P^3P) Partner
oligonucleotide
Restriction site
introduced
S116A F GGTCTAGCGCTGTCTAGCAAAC R1 Eco47III
R GACAGCGCTAGACCAGGAAAAC F1
H46A F GTTGAATATTAACGCGAACGAAAAGGCCAC R1 None
R GCCTTTTCGTTCGCGTTAATATTCAACGGT F1
H135D F CCGTTTTTTCATGACGTCTCTGTATGTGGA R1 AatII
R TCCACATACAGAGACGTCATGAAAAAACGG F2
The sequences of the partner oligonucleotides were: F1: 5P-GCTGCCGCTAGCAAATTTGGGTAGGTGGATTC-3P ; F2: 5P-TCGATTTAGAG-
CATGGGC-3P ; R1: 5P-GCCCTCGTCGACTCAAGCTTTAATATACGTACATTTAG-3P.
N.J. Tigue, J. Kay/FEBS Letters 441 (1998) 467^469 469
